预约演示
更新于：2025-12-09
Peceleganan
培来加南
更新于：2025-12-09
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段申请上市 |
首次获批日期- |
最高研发阶段(中国)申请上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C138H226N36O34 |
InChIKeyIUYWAZJIRQDBEJ-XECNVCPKSA-N |
CAS号850761-47-6 |
Sequence Code 10641
来源: *****
关联
10
项与 培来加南 相关的临床试验NCT06189638
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Antimicrobial Peptide PL-5 Topical Spray in Patients With Mild Infections of Diabetic Foot Ulcers
CTR20231275
一项评估抗菌肽PL-5喷雾剂治疗创面感染的有效性和安全性的多中心、随机、双盲、安慰剂对照的IIIb期临床试验
ChiCTR2300071255
A multicenter, randomized, double-blind, placebo-controlled phase IIIb clinical trial to assess the efficacy and safety of antibacterial peptide PL-5 Spray for wound infections
100 项与 培来加南 相关的临床结果
登录后查看更多信息
100 项与 培来加南 相关的转化医学
登录后查看更多信息
100 项与 培来加南 相关的专利（医药）
登录后查看更多信息
9
项与 培来加南 相关的文献（医药）2025-04-01Journal of Advanced Pharmaceutical Technology & Research
Cytotoxicity test and the potency of polyvinyl alcohol-based Moringa oleifera nanoparticles on cancer cell death: In vitro study
Article
作者: Syahputri, Vania ; Budhy, Theresia Indah ; Plumeriastuti, Hani ; binti Tengku Ahmad Noor, Tengku Natasha Eleena
Moringa oleifera (MO) has been explored for anticancer drug development. However, conventional extract formulations face limitations in drug delivery. Nanoparticles offer a promising alternative due to their small size, enhancing drug selectivity, efficacy, and safety. Therefore, this study aimed to characterize polyvinyl alcohol-based MO nanoparticles (NpMO) and assess their cytotoxicity and anticancer potential. Moreover, NpMO was synthesized using ultrasonication and characterized by its size, functional groups, and surface morphology. Then, an MTT assay was conducted in Vero and HeLa cells, each divided into a control group and five treatment groups (PV1–5 and PL1–5). The treatment groups received NpMO with various doses: 12.5 µg/mL, 25 µg/mL, 50 µg/mL, 100 µg/mL, and 200 µg/mL. The results were represented as OD values and percentage of viable cells, with statistical analysis performed using SPSS version 27. We found that Vero cell viability remained high at 96%, 95%, 93%, 90%, and 82.3% in PV groups, indicating no significant difference between control and PV1–PV4 groups with statistical analysis. Meanwhile, HeLa cell viability decreased to 98%, 92%, 78%, 69%, and 50.2%, with PL5 showing the lowest viability percentage. Statistical analysis confirmed a significant difference between PL5 and the other PL groups. In conclusion, NpMO showed minimal toxicity to Vero cells (>50% viability up to 200 µg/mL) but significantly reduced HeLa cell viability at 50–200 µg/mL, with the strongest effect at 200 µg/mL, indicating a potential anticancer activity.
2023-01-01Annals of surgery
Efficacy and Safety of PL-5 (Peceleganan) Spray for Wound Infections
Article
作者: Liu, Chang ; Zhang, Pihong ; Liu, Wenjun ; Song, Guodong ; Fan, Kunwu ; Rong, Xinzhou ; Zhang, Yi ; Wei, Yating ; Su, Yongtao ; Yu, Jia’ao ; Zhu, Feng ; Han, Chunmao ; Chen, Mingxia ; Xia, Chengde ; Li, Yi ; Sun, Bingwei ; Wu, Jun ; Lv, Guozhong ; Zhao, Yaohua ; Chen, Yuxin ; Zhang, Baolin ; Wang, Lei ; Ji, Geng ; Lai, Wen ; Ahemaiti, Akebaer ; Yu, Xuming ; Lin, Cai ; Chen, Xiaodong ; Dong, Hu ; Wang, Haitao ; Li, Xiaojian ; Zu, Hongxu ; Liu, Jinhui
Objective::
To assess the safety and efficacy of antimicrobial peptide PL-5 (Peceleganan) spray in the treatment of wound infections.
Background::
Antimicrobial peptide PL-5 spray is a novel topical antimicrobial agent.
Methods::
We conducted a multicenter, open-label, randomized, controlled phase IIb clinical trial to evaluate the efficacy and safety of PL-5 spray, as compared with silver sulfadiazine, in patients with skin wound infections. The primary efficacy outcome was the clinical efficacy rate on the first day after ending the treatment (D8). The secondary efficacy outcome was the clinical efficacy rate on the fifth day posttreatment (D5), the bacteria clearance rate, and the overall efficacy rate at the mentioned 2 time points. The safety outcomes included adverse reactions and pharmacokinetic analysis posttreatment.
Results::
A total of 220 patients from 27 hospitals in China were randomly assigned to 4 groups. On D8, the efficacy rate was 100.0%, 96.7%, 96.7% for the 1‰ PL-5, 2‰ PL-5, 4‰ PL-5 groups, respectively, as compared with 87.5% for the control group. The efficacy rate among the 4 groups was significantly different (P<0.05). On D5, the efficacy rate was 100.0%, 93.4%, 98.3% for the 1‰ PL-5, 2‰ PL-5, 4‰ PL-5 groups, respectively, as compared with 82.5% for the control group. The efficacy rate among the 4 groups was significantly different (P<0.05). The blood concentration of PL-5 was not detectable in pharmacokinetic analysis. No severe adverse event related to the application of PL-5 was reported.
Conclusions::
Antimicrobial peptide PL-5 spray is safe and effective for the treatment of skin wound infections.
Trial Registration::
ChiCTR2000033334.
2022-10-10Angewandte Chemie (International ed. in English)
Tandem Electrochemical Oxidative Azidation/Heterocyclization of Tryptophan‐Containing Peptides under Buffer Conditions
Article
作者: Zhuo, Xianfeng ; Xu, Xiaobin ; Chen, Hantao ; Zhang, Yiyang ; Weng, Yiyi
Abstract:
As the aromatic tryptophan (Trp) side chain plays a pivotal role in influencing the structure and function of peptides and proteins, it has become an attractive target for the late‐stage modification of these important biomolecules. Herein, we report an electrochemical approach for late‐stage functionalization of peptides containing a Trp side chain through manganese‐catalyzed tandem radical azidation/heterocyclization. This electrochemical oxidative strategy provides access to azide‐substituted tetrazolo[1,5‐a]indole‐containing peptides with broad functional group tolerance, high site selectivity, and good yields of products (up to 87 %) under mild buffer conditions. Moreover, the modified Trp‐containing peptides bearing an azide functionality are promising building blocks, paving the way for the construction of various derivatives, such as “click” chemistry products.
100 项与 培来加南 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 感染 | 申请上市 | 中国 | 2024-12-24 | |
| 伤口感染 | 临床3期 | 中国 | 2021-08-23 | |
| 糖尿病足感染 | 临床2期 | 美国 | 2024-01-30 | |
| 糖尿病足溃疡 | 临床2期 | 美国 | 2024-01-30 | |
| 细菌感染 | 临床2期 | 美国 | 2023-05-11 | |
| 继发感染 | 临床2期 | 中国 | 2020-07-28 | |
| 创伤后伤口感染 | 临床2期 | 中国 | 2018-07-24 | |
| 烧伤感染 | 临床1期 | 中国 | 2016-11-07 | |
| 糖尿病足 | 临床1期 | 中国 | 2016-11-07 | |
| 毛囊炎 | 临床1期 | 中国 | 2016-11-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
ADA2024 人工标引  | N/A | 47 | 網積簾膚鹹夢製範艱願(壓衊鹹簾艱蓋齋願構壓) = 齋艱醖夢艱鹹獵製願衊 簾築積願淵餘壓鹹餘鏇 (衊顧繭齋繭觸窪淵齋積 ) 更多 | 积极 | 2024-06-21 | ||
Placebo | 網積簾膚鹹夢製範艱願(壓衊鹹簾艱蓋齋願構壓) = 網淵蓋鹽膚顧醖築觸夢 簾築積願淵餘壓鹹餘鏇 (衊顧繭齋繭觸窪淵齋積 ) 更多 | ||||||
| - | - | 570 | 製構獵襯簾膚衊壓壓簾(鏇齋製鹽積願衊鏇艱網) = 網網鏇鏇築鬱鬱蓋窪遞 簾齋膚鹽膚衊齋襯衊築 (窪積網鹹膚簾齋壓鬱壓 ) 更多 | 非劣 | 2024-06-03 | ||
製構獵襯簾膚衊壓壓簾(鏇齋製鹽積願衊鏇艱網) = 網餘鹽鑰選繭顧醖鏇艱 簾齋膚鹽膚衊齋襯衊築 (窪積網鹹膚簾齋壓鬱壓 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用